<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39323918</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2688-4526</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>BJUI compass</Title><ISOAbbreviation>BJUI Compass</ISOAbbreviation></Journal><ArticleTitle>Influences on androgen deprivation therapy prescribing before surgery in high-risk prostate cancer.</ArticleTitle><Pagination><StartPage>874</StartPage><EndPage>884</EndPage><MedlinePgn>874-884</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/bco2.411</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To understand how best to further reduce the inappropriate use of pre-surgical androgen deprivation therapy (ADT), we investigated the determinants (influences) of ADT prescribing in urologists in two European countries using an established behavioural science approach. Additionally, we sought to understand how resource limitations caused by COVID-19 influenced this practice. Identification of key determinants, of undistributed and disrupted practice, will aid development of future strategies to reduce inappropriate ADT prescribing in current and future resource-limited settings.</AbstractText><AbstractText Label="PARTICIPANTS AND METHODS" NlmCategory="UNASSIGNED">We conducted semi-structured qualitative interviews with urologists practicing in Italy and the UK from February to July 2022. Interviews focussed on undisrupted (usual) practice and disrupted practice (changes made during COVID-19 restrictions). Codes were generated inductively and were mapped to the 14 domains of the Theoretical Domains Framework. Relevant domains of influence were identified, and the similarities and differences between the UK and Italy were distinguished.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified 10 domains that were influential to ADT prescribing in the UK and eight in Italy. The role of guidance and evidence, the cancer care setting, the patients and the urologist's beliefs and experiences were identified as areas that were influential to ADT prescribing before surgery. Twenty-one similarities and 22 differences between the UK and Italy, for usual and COVID-19 practice, were identified across these 10 domains.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Similarities and differences influencing ADT prescribing prior to surgery should be considered in behavioural strategy development and tailoring to reduce inappropriate ADT use. We gained an understanding of usual, undistributed care and resource-limited or disrupted care due to COVID-19 in two European countries. This gives an indication of how influences on ADT prescribing may change in future resource-limited circumstances and where efforts can be focused now and in future.</AbstractText><CopyrightInformation>© 2024 The Author(s). BJUI Compass published by John Wiley &amp; Sons Ltd on behalf of BJU International Company.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dunsmore</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6892-0247</Identifier><AffiliationInfo><Affiliation>Academic Urology Unit University of Aberdeen Aberdeen UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Eilidh</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1009-9732</Identifier><AffiliationInfo><Affiliation>Health Service Research Unit University of Aberdeen Aberdeen UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacLennan</LastName><ForeName>Sara J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-1405-6964</Identifier><AffiliationInfo><Affiliation>Academic Urology Unit University of Aberdeen Aberdeen UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N'Dow</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5340-0081</Identifier><AffiliationInfo><Affiliation>Academic Urology Unit University of Aberdeen Aberdeen UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornford</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7146-9258</Identifier><AffiliationInfo><Affiliation>Liverpool University Hospitals Liverpool UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esperto</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-0108-1864</Identifier><AffiliationInfo><Affiliation>Department of Urology Campus Biomedico University of Rome Rome Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavan</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7355-7625</Identifier><AffiliationInfo><Affiliation>Urology Section, Department of Surgical, Oncological and Stomatological Sciences University of Palermo Palermo Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribal</LastName><ForeName>María J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-8142-5382</Identifier><AffiliationInfo><Affiliation>Uro-Oncology Unit, Hospital Clinic University of Barcelona Barcelona Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roobol</LastName><ForeName>Monique J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-6967-1708</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Urology Section Erasmus University Medical Center Rotterdam, Cancer Institute Rotterdam The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skolarus</LastName><ForeName>Ted A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0002-5859-8151</Identifier><AffiliationInfo><Affiliation>VA Ann Arbor Healthcare System Ann Arbor Michigan USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Chicago Chicago Illinois USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacLennan</LastName><ForeName>Steven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2691-8421</Identifier><AffiliationInfo><Affiliation>Academic Urology Unit University of Aberdeen Aberdeen UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>BJUI Compass</MedlineTA><NlmUniqueID>101764975</NlmUniqueID><ISSNLinking>2688-4526</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">behaviour change</Keyword><Keyword MajorTopicYN="N">determinants</Keyword><Keyword MajorTopicYN="N">de‐implementation</Keyword><Keyword MajorTopicYN="N">influences</Keyword><Keyword MajorTopicYN="N">intervention</Keyword><Keyword MajorTopicYN="N">neoadjuvant androgen deprivation therapy</Keyword><Keyword MajorTopicYN="N">practice change</Keyword><Keyword MajorTopicYN="N">qualitative methods</Keyword><Keyword MajorTopicYN="N">strategies</Keyword></KeywordList><CoiStatement>Monique J. Robool, Steven MacLennan and Jennifer Dunsmore have received an EAU Research Foundation seeding grant. Steven MacLennan and Jennifer Dunsmore secured the University of Aberdeen Elphinstone PhD Student Scholarship and stipend funds from Cancer Research Aberdeen and North East Scotland (CRANES), Registered charity number: SC034542. Philip Cornford is the Chair of the EAU Prostate Cancer Panel and receives consulting fees from AstraZeneca, Ipsen, Janssen; payments or honoraria for lectures/ events from Accord, Bayer and Ipsen; and support to attend meetings from Ipsen, Jassen and Bayer. Francesco Esperto is a board member for YAU endourology and stones group, YOU, SIU and EBU. Nicola Pavan receives consulting fees for Ipsen and Ferring and payments or honoraria for lectures/events from Accord. Ted A. Skolarus received grant from the US National Institutes of Health National Cancer Institute R37 CA222885: De‐implementation of low value castration for men with prostate cancer and participates on the Data Safety and Monitoring Board: US NHBLI U01HL159880 Eliminating Monitor Overuse (EMO) Hybrid Effectiveness‐Deimplementation Trial, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania. James N'Dow, María J. Ribal and Sara J. MacLennan do not have any conflict of interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39323918</ArticleId><ArticleId IdType="pmc">PMC11420097</ArticleId><ArticleId IdType="doi">10.1002/bco2.411</ArticleId><ArticleId IdType="pii">BCO2411</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
WHO
. COVID‐19 has caused major disruptions and backlogs in health care, new WHO study finds [Internet]. 2022.  [cited 2023 Sep 20]; Available from: https://www.who.int/europe/news/item/20-07-2022-covid-19-has-caused-major-disruptions-and-backlogs-in-health-care--new-who-study-finds
</Citation></Reference><Reference><Citation>Lai AG, Pasea L, Banerjee A, Hall G, Denaxas S, Chang WH, et al. Estimated impact of the COVID‐19 pandemic on cancer services and excess 1‐year mortality in people with cancer and multimorbidity: near real‐time data on cancer care, cancer deaths and a population‐based cohort study. BMJ Open. 2020;10(11):e043828. 10.1136/bmjopen-2020-043828</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-043828</ArticleId><ArticleId IdType="pmc">PMC7674020</ArticleId><ArticleId IdType="pubmed">33203640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed K, Hayat S, Dasgupta P. Global challenges to urology practice during the COVID‐19 pandemic. BJU Int. 2020;125(6):E5–E6. 10.1111/bju.15082</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.15082</ArticleId><ArticleId IdType="pmc">PMC7262148</ArticleId><ArticleId IdType="pubmed">32275792</ArticleId></ArticleIdList></Reference><Reference><Citation>British Association of Urological Surgeons . COVID‐19 strategy for the interim management of prostate cancer prepared by the BAUS section of oncology. 2020.</Citation></Reference><Reference><Citation>Mitropoulos D, Chlosta P, Häggman M, Ström T, Markussis V. Androgen deprivation monotherapy usage in non‐metastatic prostate cancer: results from eight European countries. Cent European J Urol. 2021;74(2):161–168. 10.5173/ceju.2021.0343.R1</Citation><ArticleIdList><ArticleId IdType="doi">10.5173/ceju.2021.0343.R1</ArticleId><ArticleId IdType="pmc">PMC8318023</ArticleId><ArticleId IdType="pubmed">34336233</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornford P, Smith EJ, MacLennan S, Pereira‐Azevedo N, Roobol MJ, Lumen N, et al. IMAGINE—IMpact Assessment of Guidelines Implementation and Education: the next frontier for harmonising urological practice across Europe by improving adherence to guidelines. Eur Urol. 2021;79(2):173–176. 10.1016/j.eururo.2020.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2020.10.011</ArticleId><ArticleId IdType="pubmed">33129581</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLennan S, Azevedo N, Duncan E, Dunsmore J, Fullwood L, Lumen N, et al. Mapping European Association of Urology Guideline Practice Across Europe: an audit of androgen deprivation therapy use before prostate cancer surgery in 6598 cases in 187 hospitals across 31 European countries. Eur Urol. 2023;83(5):393–401. 10.1016/j.eururo.2022.12.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2022.12.031</ArticleId><ArticleId IdType="pubmed">36639296</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgia G, Russo GI, Tubaro A, Bortolus R, Randone D, Gabriele P, et al. Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross‐sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. BJU Int. 2016;117(6):867–873. 10.1111/bju.13307</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.13307</ArticleId><ArticleId IdType="pubmed">26332130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogenhout R, de Vos II, Remmers S, Venderbos LDF, Busstra MB, Roobol MJ. Detailed evaluation of androgen deprivation overtreatment in prostate cancer patients compared to the European Association of Urology guidelines using long‐term data from the European Randomised Study of Screening for Prostate Cancer Rotterdam. Eur Urol Open Sci. 2022;42:42–49. 10.1016/j.euros.2022.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euros.2022.06.004</ArticleId><ArticleId IdType="pmc">PMC9334877</ArticleId><ArticleId IdType="pubmed">35911085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ficarra V, Novara G, Abrate A, Bartoletti R, Crestani A, De Nunzio C, et al. Urology practice during the COVID‐19 pandemic. Minerva Urol Nefrol. 2020;72(3):369–375. 10.23736/S0393-2249.20.03846-1</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0393-2249.20.03846-1</ArticleId><ArticleId IdType="pubmed">32202401</ArticleId></ArticleIdList></Reference><Reference><Citation>Neamţiu L, Martos C, Giusti F, Negrão Carvalho R, Randi G, Dimitrova N, et al. Impact of the first wave of the COVID‐19 pandemic on cancer registration and cancer care: a European survey. Eur J Public Health. 2022;32(2):311–315. 10.1093/eurpub/ckab214</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurpub/ckab214</ArticleId><ArticleId IdType="pmc">PMC8975538</ArticleId><ArticleId IdType="pubmed">34935934</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravas S, Fournier G, Oya M, Summerton D, Scarpa RM, Chlosta P, et al. Prioritising urological surgery in the COVID‐19 era: a global reflection on guidelines. Eur Urol Focus. 2020;6(5):1104–1110. 10.1016/j.euf.2020.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euf.2020.06.006</ArticleId><ArticleId IdType="pmc">PMC7294295</ArticleId><ArticleId IdType="pubmed">32571743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribal MJ, Cornford P, Briganti A, Knoll T, Gravas S, Babjuk M, et al. European Association of Urology Guidelines Office Rapid Reaction Group: an organisation‐wide collaborative effort to adapt the European Association of Urology guidelines recommendations to the coronavirus disease 2019 era. Eur Urol. 2020;78(1):21–28. 10.1016/j.eururo.2020.04.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2020.04.056</ArticleId><ArticleId IdType="pmc">PMC7183974</ArticleId><ArticleId IdType="pubmed">32376137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A war on two fronts: cancer care in the time of COVID‐19. Ann Intern Med. 2020;172(11):756–758. 10.7326/M20-1133</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-1133</ArticleId><ArticleId IdType="pmc">PMC7133056</ArticleId><ArticleId IdType="pubmed">32219410</ArticleId></ArticleIdList></Reference><Reference><Citation>Società Italiana di Urologia . Correspondence with SIU about changes to guidance. 2023.</Citation></Reference><Reference><Citation>Michie S, Johnston M, Francis J, Hardeman W, Eccles M. From theory to intervention: mapping theoretically derived behavioural determinants to behaviour change techniques. Appl Psychol. 2008;57(4):660–680. 10.1111/j.1464-0597.2008.00341.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-0597.2008.00341.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimshaw JM, Patey AM, Kirkham KR, Hall A, Dowling SK, Rodondi N, et al. De‐implementing wisely: developing the evidence base to reduce low‐value care. BMJ Qual Saf. 2020;29(5):409–417. 10.1136/bmjqs-2019-010060</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjqs-2019-010060</ArticleId><ArticleId IdType="pmc">PMC7229903</ArticleId><ArticleId IdType="pubmed">32029572</ArticleId></ArticleIdList></Reference><Reference><Citation>
Sherrington A. 2 years of COVID‐19 on GOV.UK [Internet]
Government Digital Service; 2022.  [cited 2023 Sep 13]; Available from: https://gds.blog.gov.uk/2022/07/25/2-years-of-covid-19-on-gov-uk/
</Citation></Reference><Reference><Citation>Bosa I, Castelli A, Castelli M, Ciani O, Compagni A, Galizzi MM, et al. Response to COVID‐19: was Italy (un)prepared? Health Econ Policy Law. 2022;17(1):1–13. 10.1017/S1744133121000141</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1744133121000141</ArticleId><ArticleId IdType="pmc">PMC7985656</ArticleId><ArticleId IdType="pubmed">33663622</ArticleId></ArticleIdList></Reference><Reference><Citation>Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7(1):37. 10.1186/1748-5908-7-37</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1748-5908-7-37</ArticleId><ArticleId IdType="pmc">PMC3483008</ArticleId><ArticleId IdType="pubmed">22530986</ArticleId></ArticleIdList></Reference><Reference><Citation>Skolarus TA, Forman J, Sparks JB, Metreger T, Hawley ST, Caram MV, et al. Learning from the “tail end” of de‐implementation: the case of chemical castration for localized prostate cancer. Implement Sci Commun. 2021;2(1):124. 10.1186/s43058-021-00224-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43058-021-00224-8</ArticleId><ArticleId IdType="pmc">PMC8555144</ArticleId><ArticleId IdType="pubmed">34711274</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam R, Tinmouth AT, Francis JJ, Brehaut JC, Born J, Stockton C, et al. A cross‐country comparison of intensive care physicians' beliefs about their transfusion behaviour: a qualitative study using the Theoretical Domains Framework. Implement Sci. 2012;7(1):93. 10.1186/1748-5908-7-93</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1748-5908-7-93</ArticleId><ArticleId IdType="pmc">PMC3527303</ArticleId><ArticleId IdType="pubmed">22999460</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, et al. What is an adequate sample size? Operationalising data saturation for theory‐based interview studies. Psychol Health. 2010;25(10):1229–1245. 10.1080/08870440903194015</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08870440903194015</ArticleId><ArticleId IdType="pubmed">20204937</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Commission
. European Cancer Information System [Internet]. [cited 2023 Jun 27]; Available from: https://ecis.jrc.ec.europa.eu/explorer.php?$0‐4$1‐All$4‐1$3‐34$6‐0,85$5‐2020,2040$7‐7$21‐0$CLongtermChart1_1$X0_‐1‐AE27$CLongtermChart1_2$X1_‐1‐AE27$CLongtermChart1_3$X2_‐1‐AE27$CLongtermChart1_4$X3_14‐$X3_‐1‐AE27$CLongtermTable1_6$X4_‐1‐AE27
</Citation></Reference><Reference><Citation>Augustsson H, Ingvarsson S, Nilsen P, von Thiele Schwarz U, Muli I, Dervish J, et al. Determinants for the use and de‐implementation of low‐value care in health care: a scoping review. Implement Sci Commun. 2021;2(1):13. 10.1186/s43058-021-00110-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43058-021-00110-3</ArticleId><ArticleId IdType="pmc">PMC7860215</ArticleId><ArticleId IdType="pubmed">33541443</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahim C, Acai A, McConnell MM, Wright FC, Sonnadara RR, Simunovic M. Use of the theoretical domains framework and behaviour change wheel to develop a novel intervention to improve the quality of multidisciplinary cancer conference decision‐making. BMC Health Serv Res. 2020;20(1):578. 10.1186/s12913-020-05255-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-020-05255-w</ArticleId><ArticleId IdType="pmc">PMC7313182</ArticleId><ArticleId IdType="pubmed">32580767</ArticleId></ArticleIdList></Reference><Reference><Citation>Skolarus TA, Hawley ST, Forman J, Sales AE, Sparks JB, Metreger T, et al. Unpacking overuse of androgen deprivation therapy for prostate cancer to inform de‐implementation strategies. Implement Sci Commun 2024;5:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11005280</ArticleId><ArticleId IdType="pubmed">38594740</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton WE, Chambers DA. Unpacking the complexities of de‐implementing inappropriate health interventions. Implement Sci. 2020;15(1):2. 10.1186/s13012-019-0960-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13012-019-0960-9</ArticleId><ArticleId IdType="pmc">PMC6950868</ArticleId><ArticleId IdType="pubmed">31915032</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>